China / Boehringer Ingelheim's Stroke Rehab Centre Success & Continuing China Push
In March 2018, German pharma player Boehringer Ingelheim (BI)‘s Consanas Rehabilitation and the Shanghai…
Hainan Dongfang Dahui Starch Products Co., Ltd. China
Last updated: 13.02.2014
Address: Guilinyang Industrial Development Zone, Haikou, Hainan, China
Tel: 0898-65710069
Company description
Hainan Dongfang Dahui Starch Products Co., Ltd. is a national key leading enterprise in agricultural industry which owned the state’s financial investment, integrating cassava cultivation, production , deep-processing, etc, and owning 6 production lines to produce chemical modified starch, drying modified starch, pre-gelatinized modified starch, glutinous rice starch, etc, which supply series of high-quality cassava starch and modified starch products, widely used in the fields of food, paper, textile, feed, construction materials, petroleum, chemical industry, etc.. It has passed Certification of ISO9001-2008 Quality Management System, and HACCP-EC-01 Certification of Food Safety Management System. In 2006, it is honored as National Agricultural Products Processing Demonstration Enterprise by China Agricultural Department. Meanwhile, it is the only manufacture of organic cassava starch in China, which passed the organic certification of Canada, USDA, IFOAM and OFDC organization.
Products and services
Food Series
Modified starch glue prime
Feed Series
Chemical Building Materials Series
Modified starch glue prime
Petroleum chemicals Series
Related
Haijun Dong – CEO, BioDuro-Sundia
Dr Haijun Dong, recently appointed CEO of BioDuro-Sundia, shares his priorities for the newly merged entity, one of…
China / Public Insurance Coverage for Rare Disease Patients: Beijing & Shanghai Surprisingly Low in New City Ranking
Kevin Rufang Huang, president and founder of the Chinese Organization for Rare Disorders (CORD), outlines the…
China / AstraZeneca/Junshi anti-PD-1 Tie-Up; New UK Biologics Plan for Pharmaron; Clover’s $230 Million Investment Boost
The latest from Chinese pharma, including a new deal between AstraZeneca and Junshi Biosciences; Innoforce and…
China / Yangtze River Pharmaceutical Group (YRPG) in Profile
One of the largest domestic pharma companies in China (ranking number one from 2014 to 2019), Yangtze River…
China / HiFiBiO CEO on the Keys to Global Biotech Success
HiFiBiO Therapeutics cofounder, CEO and CSO Dr Liang Schweizer fits the profile of a Chinese biotech CEO to a T:…
China / New Drug Approvals 2020
Writing in the February edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk Pharma China and Xiaoxi…
Liang Schweizer – CEO & CSO, HiFiBiO Therapeutics
Dr Liang Schweizer introduces immunotherapy-focused biotech HiFiBiO Therapeutics, the main advantages of the…
China / National Reimbursement Drug List (NRDL) 2020: What Reward for Innovation?
Eric Bouteiller examines the most recent update to China’s National Reimbursement Drug List, the positive impact…
China / New Year, New Round of Drug Price Cuts
Since China first announced its ground-breaking volume-based procurement (VBP) pilot program to reduce drug…
China / 5 Top Trends in Healthcare & Biopharma in 2020
2020 has been eventful – perhaps the understatement of the year – but despite the novel coronavirus being…
Global / 2020's Top 7 Biotech IPOs In Profile
Following the recent news of Remegen’s massive USD 515 million IPO in November 2020, we bring you profiles of…
